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Abstract
Background: In a previous study, we demonstrated that the thickness of epicardial adipose tissue (EAT), measured by 
echocardiography, was increased in patients with metabolic syndrome (MS) and coronary artery disease (CAD). Several 
studies on obese patients, however, failed to demonstrate any relationship between EAT and CAD. We hypothesized 
that body mass index (BMI) affected the link between EAT and MS and CAD.
Methods: We consecutively enrolled 643 patients (302 males, 341 females; 59 ± 11 years), who underwent 
echocardiography and coronary angiography. The EAT thickness was measured on the free wall of the right ventricle at 
the end of diastole. All patients were divided into two groups: high BMI group, ≥27 kg/m2 (n = 165), and non-high BMI 
group, < 27 kg/m2 (n = 478).
Results: The median and mean EAT thickness of 643 patients were 3.0 mm and 3.1 ± 2.4 mm, respectively. In the non-
high BMI group, the median EAT thickness was significantly increased in patients with MS compared to those without 
MS (3.5 vs. 1.9 mm, p < 0.001). In the high BMI group, however, there was no significant difference in the median EAT 
thickness between patients with and without MS (3.0 vs. 2.5 mm, p = 0.813). A receiver operating characteristic (ROC) 
curve analysis predicting MS revealed that the area under the curve (AUC) of the non-high BMI group was significantly 
larger than that of the high BMI group (0.659 vs. 0.506, p = 0.007). When compared to patients without CAD, patients 
with CAD in both the non-high and high BMI groups had a significantly higher median EAT thickness (3.5 vs. 1.5 mm, p 
< 0.001 and 4.0 vs. 2.5 mm, p = 0.001, respectively). However, an ROC curve analysis predicting CAD revealed that the 
AUC of the non-high BMI group tended to be larger than that of the high BMI group (0.735 vs. 0.657, p = 0.055).
Conclusions: While EAT thickness was significantly increased in patients with MS and CAD, the power of EAT thickness 
to predict MS and CAD was stronger in patients with BMI < 27 kg/m2. These findings showed that the measurement of 
EAT thickness by echocardiography might be especially useful in an Asian population with a non-high BMI, less than 27 
kg/m2.
Background
Central obesity (visceral adipose tissue) correlates
strongly with the development of metabolic syndrome
(MS) and coronary artery disease (CAD) [1]. There are
ways to estimate visceral adipose tissue (VAT). Recently,
there are several reports that proposed echocardio-
graphic epicardial adipose tissue (EAT) as an easy and
reliable imaging indicator of VAT. It is widely known that
EAT thickness measured by echocardiography has a good
correlation with abdominal adipose tissue measured by
computed tomography (CT) and magnetic resonance
imaging (MRI) [2,3].
In our previous study, the EAT thickness increased lin-
early as the MS score increased and the EAT was thicker
in patients with MS than in those without MS. The EAT
was thicker in patients with significant CAD than in
those without CAD. We suggested that EAT thickness
measured by echocardiography was a good surrogate
* Correspondence: shinjh@ajou.ac.kr
1 Department of Cardiology, Ajou University School of Medicine, Suwon, Korea
† Contributed equally
Full list of author information is available at the end of the articlePark et al. Cardiovascular Diabetology 2010, 9:29
http://www.cardiab.com/content/9/1/29
Page 2 of 8
marker for MS and CAD [3,4]. In another study, EAT
thickness was also related to MS and the presence and
extent of CAD [5].
Several groups have failed to demonstrate the correla-
tion between EAT and CAD. Chaowalit et al. reported
that EAT thickness is not associated with the presence,
extent or severity of CAD in patients [6]. Gorter et al.
reported that neither pericardial fat nor visceral abdomi-
nal fat correlated with CAD in patients with body mass
index (BMI) ≥25 kg/m2 [7]. In these reports, the subjects
were relatively obese compared with the subjects in our
previous study. In our study, the mean BMI of the sub-
jects was 25.2 ± 3.1 kg/m2. In the report of Chaowalit et
al., the mean BMI of the subjects was 28.8 ± 5.5 kg/m2 [6].
The inconsistent results regarding the correlation
between EAT and CAD might be due to differences in
BMI of the study population. In one study, the correlation
between pericardial fat and coronary plaque was seen in
the non-obese patients but not in the overweight patients
[8]. To evaluate the correlation between pericardial fat
and CAD, it has been suggested that it is necessary to
divide study subjects according to the degree of obesity,
as obesity itself is frequently associated with various met-
abolic and circulatory factors and is known to be an inde-
pendent risk factor for CAD [9]. Mazur et at. failed to
demonstrate the correlation between EAT and MS. In
that report, the subjects included obese children with
BMI > 97 percentile as defined by the International Obe-
sity Task Force [10,11]. In 2004, Kip et al. reported that
the clinical effects of VAT on patients with MS differed
between the normal BMI group and the obese group. In
that study , the patients with MS and normal BMI had
poorer clinical outcome compared to the patients with
MS who were obese [12]. We hypothesized that the pre-
dicting ability of EAT thickness for MS and CAD is
affected by BMI.
Methods
Study population
The EAT thickness was measured consecutively in 643
patients (mean age 59 ± 11 years; 302 males, 341 females)
who underwent their first coronary angiography due to
chest pain. The medical records of all patients were retro-
spectively reviewed after informed consent was obtained
from patients. EAT has been proposed as a source of sev-
eral inflammatory mediators [13-15]. We tried to exclude
the acute systemic inflammatory effect to avoid con-
founding the role of EAT and diagnosis of MS. We
excluded patients from the study if they had any of the
following: active inflammation, a history of prior revascu-
larization, heart failure, cardiomyopathy or acute myo-
cardial infarction. We identified MS if there were more
than 3 of 5 criteria based on the updated Adult Treatment
Panel III (ATP III) guidelines. The MS score was defined
as the number of criteria present. Adjusting values specif-
ically for an Asian population, central obesity was defined
as waist circumference of ≥90 cm in men and ≥80 cm in
women [16]. Upon quantitative analysis of the coronary
angiograms, significant CAD was considered to be the
presence of one or more stenoses, ≥50% in diameter, of a
major epicardial vessel. The major epicardial vessels were
defined as the left main coronary artery that divides into
the left anterior descending and circumflex branches, and
the right coronary artery.
Measurement of echocardiographic epicardial adipose 
tissue
Two-dimensional transthoracic echocardiography was
performed. Recordings of six cycles of the two-dimen-
sional parasternal long-axis were obtained. We enlarged
each view for better visualization and accurate measure-
ment of EAT thickness. The measurement of EAT thick-
ness was done offline through the DICOM system and
performed on the free wall of the right ventricle (RV) in
the still image of a 2-D echocardiogram at end diastole on
the parasternal long-axis. We preferred the area of above
the RV to measure EAT thickness, because this area is
recognized as having the thickest EAT layer. In addition,
the parasternal long-and short-axis views allow the most
accurate measurement of EAT thickness with optimal
cursor beam orientation in each view. We measured the
thickest point of EAT in each cycle. The average value of
the EAT thickness was calculated (Figure 1).
Coronary angiography
Quantitative coronary angiographic analysis was per-
formed by one experienced technician who was unaware
of the patients' clinical information. Angiographic data
were analyzed for the presence of CAD.
Figure 1 Echocardiographic measurement of epicardial adipose 
tissue thickness. Parasternal long-axis view at the mitral valve level. 
EAT, epicardial adipose tissue; RV, right ventriclePark et al. Cardiovascular Diabetology 2010, 9:29
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Statistical analysis
The SPSS 12.0 (SPSS inc., Chicago, Illinois, USA) statisti-
cal software package was used for all calculations. Data
are shown as the mean ± standard deviation (SD) and the
median values for continuous variables and as percent-
ages for categorical variables. p < 0.05 indicates statistical
significance. We compared the characteristics of patients
who had BMI ≥27 kg/m2 (high BMI group) to those with
BMI < 27 kg/m2 (non-high BMI group). Comparisons of
continuous variables were performed using the unpaired
Student t test. As the skewness of the EAT thickness was
0.749 (p < 0.001) using the Kolmogrov-Smirnov test,
comparisons of the EAT thickness according to the pres-
ence of MS in the high and non-high BMI groups and the
presence of CAD in 2 groups were performed using the
Wilcoxon rank-sum test rather than the parametric test.
Comparisons of the EAT thickness according to the MS
score were done using the Kruskal-Wallis test. A receiver
operation characteristic (ROC) curve analysis was used
to assess the discrimination of MS and CAD based on the
EAT thickness according to the BMI. Medcalc 10.4.8
(Medcalc software inc., Mariakerke, Belgium) statistical
software was used for comparing the area under curve
(AUC) of the ROC curve between groups.
One sample paired t test was performed to evaluate
inter- and intraobserver variability in the measurement of
EAT from 30 randomly selected subjects.
Results
Clinical characteristics
Clinical characteristics according to BMI are summarized
in Table 1. Seventy-four percent of patients were included
in the non-high BMI group. The non-high BMI group
consisted of 478 patients (252 males) with a mean age of
59 ± 11 years. Forty-nine percent of non-high BMI group
met the criteria of the MS. The high BMI group was con-
sisted of 165 patients (80 males) with a mean age of 59 ±
11 years. Eighty-one percent of the high BMI group was
diagnosed with MS.
Compared to the non-high BMI group, subjects in the
high BMI group had significantly higher rates of hyper-
tension, diabetes and metabolic syndrome and higher lev-
els of total cholesterol, LDL-cholesterol and triglycerides.
The median and mean EAT thickness of 643 patients
were 3.0 mm and 3.1 ± 2.4 mm, respectively. In the non-
high BMI group, the median and mean EAT thickness
were 2.8 mm and 3.0 ± 2.4 mm, respectively. In the high
BMI group, the median and mean EAT thickness were 3.0
mm and 3.5 ± 2.4 mm, respectively. The median EAT
thickness was significantly increased in the high BMI
group compared to that of the non-high BMI group (3.0
vs. 2.8 mm, p = 0.01). The absolute values of the mean
paired differences were 0.0200 ± 0.39637, p = 0.773 and
0.0033 ± 0.46866, p = 0.969 for inter- and intraobserver
variability of the EAT measurement, indicating good
reproducibility.
Epicardial adipose tissue thickness as a predictor of 
metabolic syndrome according to body mass index
The median EAT thickness was significantly increased in
patients with MS compared to those without MS (3.3 vs.
2.0 mm, p < 0.001). EAT thickness also increased with an
increase in the number of MS components (p < 0.001).
In the non-high BMI group, the median EAT thickness
was significantly increased in patients with MS compared
to those without MS (3.5 vs. 1.9 mm, p < 0.001, Figure 2).
The median EAT thickness values for those with 0, 1, 2, 3,
4, or 5 MS components were 1.3, 1.7, 2.0, 3.5, 3.5, and 3.2
mm, respectively. The median EAT thickness signifi-
cantly increased with an increase in the number of MS
components (p < 0.001, Figure 3-A).
In the high BMI group, the median EAT thickness was
not significantly increased in patients with MS compared
to those without MS (3.0 vs. 2.5 mm, p = 0.813, Figure 2).
The median EAT thickness values for subjects with 0, 1,
2, 3, 4, or 5 MS components were 2.5, 2.3, 3.3, 3.0, 3.0, and
4.5 mm, respectively. The median EAT thickness did not
increase with an increase in the number of MS compo-
nents (p = 0.121, Figure 3-B).
The ROC curves of the EAT thickness in predicting MS
yielded an AUC of 0.659 in the non-high BMI group and
0.506 in the high BMI group. When comparing the AUC
of the 2 groups, the AUC to predict MS was significantly
higher in the non-high BMI group compared to the high
BMI group (p = 0.007, Figure 4).
Epicardial adipose tissue thickness as a predictor of 
coronary artery disease according to body mass index
The median EAT thickness was significantly increased in
patients with CAD compared to patients without CAD
(1.7 vs. 3.5 mm, p < 0.001). When compared to subjects
without CAD, patients with CAD in both the non-high
and high BMI groups had a median EAT thickness that
was significantly increased (3.5 vs. 1.5 mm, p < 0.001 and
4.0 vs. 2.5 mm, p = 0.001, respectively, Figure 5). In addi-
tion to well-known CAD risk factors, such as age, smok-
ing, hypertension, and diabetes, EAT thickness was an
independent factor associated with CAD in both groups
(Table 2). The ROC curves of the EAT thickness in pre-
dicting CAD yielded an AUC of 0.657 in the non-high
BMI group and 0.735 in the high BMI group. When com-
paring the AUC of the 2 groups, the ROC curve analysis
predicting CAD revealed that the AUC of the BMI < 27
kg/m2 group tended to be larger than that of the BMI ≥27
kg/m2 (p = 0.055, Figure 6).
Discussion
The present study demonstrated that the power of EAT
thickness measured by echocardiography to predict MSPark et al. Cardiovascular Diabetology 2010, 9:29
http://www.cardiab.com/content/9/1/29
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Table 1: Baseline characteristics according to body mass index (n = 643)
Characteristics BMI < 27 kg/m2
(n = 478)
BMI ≥ 27 kg/m2
(n = 165)
p
Male, No 252 (53%) 80 (48%) NS
Age (year-old) 59 ± 11 59 ± 11 NS
EAT thickness (mm)
Mean ± SD 3.0 ± 2.4 3.5 ± 2.4 0.01
Median 2.8 3.0 0.01
Body Mass Index (kg/m2) 23.7 ± 2.4 29.0 ± 2.1 < 0.001
Waist circumference (cm)
Male 87.0 ± 8.0 97.1 ± 7.5 < 0.001
Female 84.7 ± 9.1 95.0 ± 7.6 < 0.001
Total cholesterol (mg/dl) 170.6 ± 35.3 182.32 ± 39.2 0.001
LDL cholesterol (mg/dl) 97.0 ± 30.0 104.4 ± 33.7 0.025
Triglyceride (mg/dl) 142.1 ± 83.3 183.1 ± 109.5 < 0.001
HDL cholesterol (mg/dl)
Male 44.0 ± 10.7 40.3 ± 9.2 0.013
Female 48.3 ± 12.7 47.1 ± 11.3 NS
Fasting glucose (mg/dl) 115.0 ± 33.9 120.0 ± 43.4 NS
Hypertension, No 313 (66%) 125 (76%) 0.012
Diabetes, No 295 (62%) 128 (78%) < 0.001
Smoking, No 156 (33%) 41 (25%) 0.048
Metabolic Syndrome, No 243 (49%) 133 (81%) < 0.001
Metabolic Score 2.5 ± 1.3 3.3 ± 1.0 < 0.001
Coronary Artery Disease, No 247 (52%) 74 (45%) NS
Normal & minimal CAD 230 (48%) 91 (55%) NS
1 vessel 111 (23%) 31 (19%) NS
2 vessel 69 (14%) 24 (15%) NS
3 vessel 65 (14%) 19 (12%) NS
Medication, No
Aspirin 115 (24%) 37(22%) NS
Beta blockers 49 (10%) 19 (12%) NS
Calcium channel blockers 89 (19%) 33 (20%) NS
ACE inhibitors 23 (5%) 4 (2%) NS
AT II receptor blockers 58 (12%) 22 (13%) NS
Statins 46 (10%) 22 (13%) NS
Nitrates 51 (11%) 16 (10%) NS
Diuretics 46 (10%) 18 (11%) NS
EAT, epicardial adipose tissue; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CAD, coronary artery disease; ACE, angiotensin 
converting enzyme; AT, angiotensin; SD, standard deviation; NS, not significant
was stronger in patients with BMI < 27 kg/m2. Our results
also demonstrated a strong correlation between EAT
thickness and CAD, especially in patients with a non-high
BMI. Our study might explain previous inconsistent
results from various studies regarding the correlation
between EAT and CAD [3,6,7,17]. Recently Gorter et al.
reported that, in patients with BMI < 27 kg/m2, increased
EAT volume and pericoronary fat volume as measured by
CT w e r e  as socia t ed wit h CAD a nd e x t e nsi ve c or ona ry
artery calcium (CAC) [7]. Although we used a differentPark et al. Cardiovascular Diabetology 2010, 9:29
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way to evaluate EAT, using echocardiography to measure
EAT thickness, the results were consistent with those of
Gorter et al. In addition to these findings, we demon-
strated that the predicting value of EAT thickness for MS
might be more useful in patients with a non-high BMI.
The results of our study suggest that different standards
of EAT thickness according to BMI are needed to predict
MS and CAD.
In the present study, we used 27 kg/m2 as the cut-off
point; any number equal to 27 and above was the BMI for
obesity. The relative percentage of body fat at different
BMIs clearly varies within populations. The correspond-
ing cut-off point for obesity, based on the assumption
that the percentage of body fat in the Asian population is
the same as the percentage of body fat in the Western
population, was lower than the existing WHO cut-off
point for obesity, 30 kg/m2 [18]. Western studies have
reported that a BMI ≥ 30 kg/m2 group has a greater risk of
death caused by cardiovascular diseases [19,20]. Some
recent studies on Asian populations showed that low BMI
influences cardiovascular diseases [18,21]. In 2007, the
Kangwha Cohort Study reported that the risk of cardio-
vascular diseases was significantly increased in the BMI ≥
27 kg/m2 group in the Korean population [22]. This study
included the Korean population, so we decided that the
cut-off point for obesity was 27 kg/m2 instead of 30 kg/
m2.
Figure 2 Distribution of the thickness of epicardial adipose tissue 
according to body mass index and metabolic syndrome.
Figure 3 Distribution of the thickness of epicardial adipose tissue 
according to body mass index and metabolic score. (A) Non-high 
BMI group. (B) High BMI group.
 
A
B
Figure 4 ROC curve analysis to demonstrate the discriminatory 
power of the thickness of epicardial adipose tissue in the diagno-
sis of metabolic syndrome according to body mass index. AUC, 
the area under the curve  
Figure 5 Distribution of the thickness of epicardial adipose tissue 
according to body mass index and coronary artery disease.Park et al. Cardiovascular Diabetology 2010, 9:29
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Several biomolecular studies in humans have shown
that EAT is metabolically active and an important source
of both pro-inflammatory adipokines, such as tumor
necrosis factor-α, interleukin 1, interleukin 6 and nerve
growth factor, and anti-inflammatory adipokines, such as
adiponectin and adrenomedullin [13-15]. The regulation
and metabolism of pro- and anti-inflammatory mediators
secreted by EAT have been linked to insulin sensitivity
[23]. EAT has been shown to express a pathogenic mRNA
profile of pro-inflammatory adipokines in patients with
CAD [13]. One study showed that expression of adi-
ponectin, an anti-inflammatory adipokine, in EAT was
significantly lower in patients with CAD compared to
those without CAD [14]. EAT thickness has also been
shown to be related to markers of insulin resistance and
inflammation [2]. For example, one study demonstrated
that obesity leads to adipocyte hypertrophy, which
increases the secretion of pro-inflammatory adipokines
and decreases the secretion of anti-inflammatory adipok-
ines by EAT [23]. The change of EAT thickness by obesity
might have obscured the difference between patients
with and without CAD, or with and without MS, in the
high BMI group of our study.
The second possible explanation for the weak correla-
tion between the EAT thickness and presence of MS and
CAD in the high BMI group, might be the different pro-
portion of the EAT to total amount of VAT according to
BMI. Patients with high BMI generally have more V AT ,
which includes EAT. In the high BMI group, the EAT
might make up a smaller proportion of the total VAT
Figure 6 ROC curve analysis to demonstrate the discriminatory 
power of the thickness of epicardial adipose tissue in the diagno-
sis of coronary artery disease according to body mass index. AUC, 
the area under the curve  
Table 2: Multiple logistic analysis of coronary artery disease risk factors
(A) Non-high BMI group (n = 478)
Risk factors Odds ratio (95% CI) p
Age 2.847 (1.603-5.057) < 0.001
Male 45 ≥ years
Female 55 ≥ years
Smoking 1.576 (1.014-2.448) 0.043
Hypertension 2.115 (1.385-3.230) < 0.001
Diabetes mellitus 2.139 (1.282-3.569) 0.004
EAT thickness (≥3 mm) 3.504 (2.297-5.346) < 0.001
(B) High BMI group (n = 165)
Risk factors Odds ratio (95% CI) p
Age 6.531 (2.089-20.420) < 0.001
Male 45 ≥ years
Female 55 ≥ years
Smoking 1.775 (0.763-4.129) 0.183
Hypertension 1.276 (0.6-2.712) 0.527
Diabetes mellitus 2.687 (1.222-5.911) 0.014
EAT thickness (≥3 mm) 2.341 (1.136-4.827) 0.021
EAT, epicardial adipose tissue; CI, confidence intervalPark et al. Cardiovascular Diabetology 2010, 9:29
http://www.cardiab.com/content/9/1/29
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compared to the non-high BMI group. In the high BMI
group, the EAT thickness by echocardiography might not
be representative of the total VAT owing to its smaller
proportion of the total VAT. That reason might attenuate
the predictive value of EAT thickness by echocardiogra-
phy for MS and CAD in the high BMI group. Further
study is necessary to clarify the different roles of EAT
according to BMI. Considering racial and gender differ-
ences in addition to BMI, further study will be necessary
to set the standards of EAT thickness by echocardiogra-
phy.
There are several limitations to the present study. First,
the study population was highly selective for those who
underwent their first coronary angiography due to chest
pain. Therefore, the results of the study could not be
applied to the general population. Also, it was a cross-
sectional study, not a cohort study. In a community-based
prospective cohort study, it was reported that pericardial
fat predicts incident coronary heart disease independent
of conventional risk factors. They evaluated the correla-
tion between pericardial fat and CAD without dividing
study subjects according to the degree of obesity [24]. A
prospective cohort study might be needed to elucidate
the different predicting power of EAT for MS and CAD
according to BMI in the general population. Second, EAT
thickness by echocardiography does not exactly represent
the amount of total EAT. Even though echocardiography
is not the optimal method for quantification of EAT, our
previous study showed that EAT thickness measured by
echocardiography has a good correlation with the total
amount of EAT [25]. EAT is true visceral fat deposited
around the heart. Epicardial, mesenteric, and omental fat
all share the same origin from the splanchnopleurituc
mesoderm associated with the gut [26]. EAT thickness
measured by echocardiography provides a sensitive and
specific measurement of true visceral fat, avoiding the
confounding effect caused by subcutaneous fat [27]. As
echocardiography is frequently performed in high-risk
cardiac patients, EAT thickness measured by echocar-
diography may be readily available at no extra cost.
Therefore, EAT thickness by echocardiography could be
applied as an easy and reliable imaging indicator of VAT
without radiation exposure [2,3].
Conclusions
While EAT thickness was significantly increased in
patients with MS and CAD regardless of BMI, the power
of EAT to predict MS and CAD was stronger in patients
with BMI < 27 kg/m2. These findings showed that the
measurement of EAT thickness by echocardiography
might be useful in patients with non-high BMI, especially
one less than 27 kg/m2.
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